enfortumab vedotin
seagen,astellas
['vedo', 'mibc', ' vedo', 'nmibc', 'enfortumab', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nct05014139', 'ev-104']
bca trials in progress:
ev-104: ph1 intravesical ev in bcg-unresponsive cis+/-papillary inelig/refuse rc: doses: induct x 6, maint x9 prim obj: safety/tolerability, identify mtd/rec dose, aes, dlts duration of cr, pfs, rc-free survival, pk start: jan 2022
#gu23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @AUB_Lebanon and @MCG_Urology